Remove Lipid disorders Remove Outcomes Remove Risk Factors
article thumbnail

Cholesterol’s Star Role in Dementia Prevention: New Insights from the 2024 Lancet Dementia Report 

Cardiometabolic Health Congress

Updated with the latest research since the 2020 edition, this comprehensive report underscores the potential to prevent or significantly delay dementia by targeting modifiable risk factors. The report now identifies 14 modifiable risk factors for dementia.

article thumbnail

Creative Alliances in Cardiorenal Metabolic Management: A Game Changer (Part 1) 

Cardiometabolic Health Congress

This blog post explores the development of such partnerships and their potential to transform healthcare outcomes. Engaging individuals as active participants in their care plans can significantly enhance outcomes and improve overall quality of life.

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

Reducing this risk is a key part of our commitment to driving change for this community, as we work to increase manufacturing capacity to responsibly supply this important medicine." The FDA decision is based on the results of the landmark SELECT phase 3 cardiovascular outcomes trial that examined the effect of adding Wegovy 2.4

Obesity 111